This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Neurology

Alzheimer's disease (AD)

Eukaryotic translation factor 2a kinase 3
(EIF2AK3; PERK); EIF2AK4 (GCN2)

Patient sample and mouse studies suggest inhibition of PERK or GCN2 could help treat AD. In brain samples from patients or mouse models of AD, phosphorylation of eukaryotic initiation factor 2a was greater than that in healthy controls. In mouse models of AD, hippocampal-specific depletion of either kinase improved learning and memory performance. Next steps include determining whether inhibition of PERK or GCN2 can reverse defects in synaptic plasticity or memory in mouse models of AD.

SciBX 6(35); doi:10.1038/scibx.2013.966
Published online Sept. 12, 2013

Unpatented; licensing status not applicable

Ma, T. et al. Nat. Neurosci.; published online Aug. 11, 2013;
doi:10.1038/nn.3486
Contact: Eric Klann, New York University, New York, N.Y.
e-mail:
eklann@cns.nyu.edu